Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction
Brought to you by

Latest From UbiVac

Prostate Cancer Vaccines: What’s In The Pipeline?

The sector still attracts the attention of clinical investigators and the pharmaceutical industry, despite disappointing results from another clinical-stage candidate.

Commercial Market Intelligence

OSE Immunotherapeutics To Bolster R&D, Post-Janssen Option

The exercising by Janssen Biotech of an option to develop OSE Immunotherapeutics’ Phase II-ready antibody fragment for autoimmune and transplant-associated disorders will give an early boost to the French biotech that only completed a merger several weeks ago.

Deals Clinical Trials

Selected Start-Ups (01/01)

In Vivo summarizes the technologies of several recently founded companies: Advanced BioChem Inc. provides contract protein biochemistry, immunoassay and proteomics services to companies developing pharmaceuticals and medical diagnostics tests. Arradial Inc. aims to accelerate the discovery and validation of therapeutic compounds with a personal desktop laboratory microarray screening system created jointly by Boston University and Alexion Pharmaceuticals Inc. Spun out of Evotec BioSystems AG, Direvo Biotech AG will use its directed evolution platform to optimize biomolecules for industrial applications, as well as to develop proteins for novel therapeutics. Evacyte Microarray Diagnostics Corp.'s new cancer detection device, the Optical Stretcher, uses laser beams to stretch individual cells, enabling doctors to extract very small samples to determine if cancer cells are present. Palumed SA is developing small molecule drugs for the treatment of malaria and other infectious diseases. Using technology developed by its founders at the University of Texas' MD Anderson Cancer Center and in collaboration with Tripos Inc., Signase Inc. will develop small-molecule inhibitors of protein tyrosine kinases to enhance the effectiveness of chemotherapy directed at various types of solid tumors.

See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Vaccines
UsernamePublicRestriction

Register